
    
      This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in
      combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK),
      immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult
      subjects with advanced NSCLC.
    
  